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1.Introduction
  Atherosclerosis is the primary cause of cardiovascular 
disease (CVD) and coronary heart disease (CHD). It is 
a leading cause of global morbidity and mortality in the 
modern world[1]. Atherosclerosis is a complex multi-
factorial disease. The oxidative modification theory for 
atherosclerosis postulates that oxidation of low density 
lipoprotein (LDL) is the key factor for this pathogenesis[2].
  Oxidised LDL acts a chemo attractant for monocyte, 
transforms macrophage into foam cells. It exerts cytotoxic 
effects on endothelial cells, increases thrombocyte 
activation, and stimulates migration and proliferations of 
smooth muscles cells that lead to formations of atheromatous 
lesions[2,3]. Several potentially anti-atherogenic mechanisms 
have been associated with high density lipoprotein (HDL). 
These include both the protection of LDL against dation 
and attenuation of the biological activity of Ox-LDL[4-6]. 
Antioxidant and anti-atherogenic properties of a HDL are 
noticed from associated enzyme, paraoxonase1 (PON1). 
Numerous studies have indicated that PON1 is largely 
responsible for HDL's anti-oxidative property[7-9].
  Moreover recent findings of two new PON members, PON2 
and PON3 also showed the protective role to oxidative 
stress in tissues and plasma[10,11]. PON1 is a calcium 
dependent ester hydrolase which is primarily synthesized 
in liver and associated with HDL in the plasma[12-14]. PON1 
inhibits LDL and HDL from oxidative modification and also 
scavenges oxidized phospholipids from LDL [7,8,15]. Moreover, 
various clinical epidemiological studies demonstrated that 
PON1 enzyme activity was inversely related to the risk of 
CHD and CVD[16-19].
  On the basis of clinical trial evidence, the most 
commonly prescribed lipid modifying therapies are the 
hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors, more commonly known as statin. Competitive 
inhibition of this enzyme by the statin decreases hepatocyte 
cholesterol synthesis[20]. Statin also shows beneficial effect 
on other lipid parameters, including increases in HDL 
and decreases in triglycerides (TG). In general, statin is 
regarded as a remarkably safe and well tolerated class of 
drugs. Seven statins are now approved for clinical uses, 
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which are simvastatin, cerivastatin, fluvastatin, lovastatin, 
pravastatin, atorvastatin and pitavastatin[20]. Though they 
all have a common function, but differ in term of chemical 
structures, pharmacokinetic profiles, and lipid modifying 
efficacy[21]. Simvastatin decreases serum cholesterol by 
reducing the production and increasing its rate of removal 
from the body [22]. It also reduces TC, LDL and TG levels and 
increases HDL levels. Simvastatin acts as an antioxidants, 
either directly or indirectly and may have beneficial effect 
on atherosclerosis apart from their effect on serum TC, it 
also involve in modifying endothelial functions.
  The present study was to determine the effect of 
simvastatin treatment on lipid profile, oxidative stress and 
activity of PON in hypercholesterolaemic Indian population.
2. Materials and methods
  Fifty two hypercholesterolaemic volunteers with 30-49 
yrd were selected for the study. Patients with diabetes, 
hypertension, hyperthyroidism, liver disease, renal 
dysfunction, history of myocardial infarction, coronary heart 
disease, cardiovascular disease, alcoholic, and smokers 
were excluded. Pregnancy, lactating women and participants 
taking hypolipidemic drugs and antioxidants vitamins were 
also excluded. 
  All subjects were undergone medical check-up at the 
Department of Cardiology, and were screened for medical 
history. A pre-tested questionnaire was used to collect 
information regarding medical history, smoking, and alcohol 
consumption from the participants. All cases with TC >240 
mg/dL and LDL >170 mg/dL were administrated with 
simvastatin 10mg /day for 4 months. The outcomes were 
analyzed at 0 and 4 months after medication. After 4 months 
of simvastatin treatment, hypercholesterolemia subjects had 
physically examination. The anthropometric measurements 
included weight, height, waist and hip circumference. 
Blood pressure was also measured. Clinical laboratory 
investigations included a complete blood cell count, blood 
urea nitrogen, creatinine, fasting blood sugar, liver function 
tests [alanine aminotransaminase (ALT), aspartate amino 
transaminase (AST)], and lipid profile analysis. 
  All volunteers were properly instructed to fast for 12 hours 
before venipuncture. Venous blood was collected two times, 
before and after 4 months of simvastatin administion. 5 mL 
blood was collected in a plain tube without anticoagulant and 
was allowed to clot at room temperature then centrifuged at 
3500伊g for 10 mins. The parameters included serum TC, 
TG, HDL, LDL, conjugated diene (CD), malondialdehyde 
(MDA), total antioxidant status (TAS), oxidative stress index 
(OSI) and paraoxonase activity.
  PON1 activities were determined by using paraoxon and 
phenyl acetate as substrates[23,24].
2.1. Paraoxon assay
  Paraoxonase activity was determined by measuring the 
absorbance inrease of p-nitrophenol at 405 nm. Adding 
20 毺L of serum to 1 mL Tris buffer (100 mM, pH 8.0) 
containing 2 mM CaCl2 and 1.1 mM paraoxon. The rate 
of hydrolysis of paraoxon was followed by measuring the 
liberation of p-nitrophenol at 405 nm at 37 曟 over 50 sec 
after 1 min lag time with spectrophotometer.
Activity =           (OD/min) 伊 assay volume
     ε伊 sample volume 伊 path length
  The enzyme activity was calculated from the molar 
extinction coefficient (ε) of 18 700 M-1 cm-1 at 405 nm, 
pH 8.0. Activity was expressed as catalytic concentration 
(U/L) which corresponds to the product of 1 毺M of p- 
nitrophenol/min/L of serum.
2.2. Arylesterase activity assay
  The reaction mixture contained 1.0 mM phenylacetate 
and 0.9 mM calcium chloride in 10 mM Tris-HCl buffer at 
pH 8.0. The reaction was initiated by adding 20 毺L serum 
which was pre diluted at 1:20 ratio with 10 mM Tris-buffer 
at pH 7.4. Absorbance increase of phenol was measured at 
270 nm and 37 曟 using spectrophotometer.
Activity =           (OD/min) 伊 assay volume
      ε 伊 sample volume 伊 path length
  The enzyme activity was calculated from the molar 
coefficient of 1 310 M-1 cm-1. Activity was expressed as 
catalytic concentration (U/L) which corresponds to the 
product of 1 mM of phenol per minute per liter of serum.
  The study was ethically cleared from the Institutional 
Ethical Committee. All participants signed the informed 
consent form before being enrolled for the study.
3. Results
  Forty-nine of 52 patients (94.23%) completed the study. 
The withdrawal rate in this study was 5.76% (3/52). 
Simvastatin treatment was well tolerated and none of the 
patients experienced serious adverse effects in this study. 
Three patients discontinued treatment due to loss of follow 
up.
3.1. Demographic characteristics
  The demographic characteristics of hypercholesterolaemic 
subjects were presented in Table 1. The mean age was 57.7 
years. The study population had a greater proportion of 
female than male. Out of 52 patients, males were 18 (36.4%) 
and females were 34 (63.6%). The mean of body mass index 
(BMI), waist-hip ratio (WHR), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), fasting blood sugar 
(FBS) of baseline were (25.0±3.7) kg/m2, 0.9±0.1, (132.0 
±17.8) mmHg, (80.0±11.9) mmHg, and (103.0±9.0) 
mg/dL, respectively. As shown in Table 1, there were no 
significant changes in demographic characteristics after 4 
months of simvastatin treatment.
3.2. Effect of simvastatin on lipid, CD, total peroxide, MDA, 
TAS, and OSI levels
  The mean levels of total cholesterol (TC), TG, HDL, and 
LDL at baseline were (254.00±40.00) mg/dL, (185.00 
±20.00) mg/dL, (50.10±12.50) mg/dL and (158.00± 
32.00) mg/dL, respectively. The mean levels of CD, total 
peroxide, MDA, TAS, trolox eguivalent/L and OSI at 
baseline were 0.38±0.06, [18.40 (13.60-26.60)] 毺mol 
H2O2/L, (17.60±2.70) mmol/L, (0.81±0.14) mmol/L  and 
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2.42±0.73, respectively.
  As shown in Table 2, Simvastatin treatment significantly 
decreased TC, TG, LDL, CD, total peroxide, MDA, and OSI 
levels by 24.5%, 24.4%, 22.4%, 4.4%, 13.0%, 15.2% and 
24.0%, respectively.
  Meanwhile, the mean TAS level significantly increased by 
27.3%, however, there was no significant difference in level 
of HDL at 4 months treatment of simvastatin [(50.40±9.20) 
mg/dL] when compared with the baseline level [(50.1±12.5) 
mg/dL].
  The percent (%) change of LDL was positively correlated 
with % change of TC (R2=0.63, P<0.05). There was no 
correlation between % change of TAS and % change of LDL 
(R2=0.15, P>0.05). HDL level did not increase significantly 
by Simvastatin treatment and the % change of HDL level 
was not correlated with change of lipid peroxidation 
parameter (R2=0.05).
3.3. Effect of simvastatin on PON1 activity
  The mean levels of PON1 activities towards paraoxon and 
phenyl acetate were (178±77) 毺mol/min/mL and (142± 
25) mmol/min/mL, respectively.
  As shown in Table 3 and Table 4, there was significant 
increase in PON1 activity towards paraoxon (+13.4%, 
P<0.05) but PON1 activity towards phenylacetate did not 
change significantly (+1.35%, P>0.05) after 4 month of 
simvastatin treatment. However, PON1 activity toward 
phenylacetate increased significantly in male (P<0.05). 
In this study, it was found non-significant difference of 
baseline PON1 activity towards paraoxon between male 
and female, but PON1 activity towards phenyl acetate was 
significantly different between male and female (P<0.05).
  The percent change of PON1 activity towards paraoxon 
was positively correlated with % change of TAS (R2= 0.30, 
P<0.05). 
Table 1 
Demographic characteristic of study subjects from baseline to four 
months (n=50).
Parameters
Hypercholesterolaemic subjects (n=52)
Baseline 4 months
Age (years)   57.7±7.4  58.0±7.4
BMI (kg/m2)   25.0±3.7  26.6±3.4
Waist-hip ratio     0.9±0.1    0.9±0.9
SBP (mmHg)   132.0±17.8 132 .0±25.4
DBP ( mmHg)     80.0±11.9   74 .0±11.8
FBS (mg/dL) 103.0±9.0  108.0±10.0
Table 2 
Effect on serum lipid parameters, serum CD, total peroxide, MDA, TAS, and OSI levels (n=52).    
Parameters
Hypercholesterolaemic subjects
Baseline 4 months
Serum lipid parameters TC ( mg/dL) 254.00±40.00   199.00±36.00*
TG ( mg/dL) 185.00±20.00   141.00±15.00*
HDL ( mg/dL) 50.10±12.50 50.40±9.20
LDL (mg/dL) 158.00±32.00   118.00±27.00*
Lipid peroxidation CD   0.38±0.06     0.34±0.05*
Total peroxide (毺mol H2O2/L) 18.40 (13.60-26.60) 15.90 (11.10-24.00) *
MDA (mmol/L) 17.60±2.70    14.80±2.90*
TAS ( mmol Trolox Equiv/L)   0.81±0.14     1.01±0.17*
OSI   2.42±0.73      1.79± 0.56*
  *:P<0.05.
Table 3 
PON1 activity at baseline and 4 month after simvastatin treatment (n=52).
PON activity
Hypercholesterolaemic subjects
Baseine 3 months
PON 1 levels Paraoxon hydrolysis (毺mol/min/mL) % change 178±77 196±90
Phenyl acetate hydrolysis (mmol/min/mL) % change 142±25 145±33
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4. Discussion
  Oxidative modification of LDL is believed to be the 
underlying cause in pathogenesis of atherosclerosis[2]. 
With this concept the prevention of atherosclerosis and 
its consequence could be limited by reducing the ox-
LDL levels and oxidative stress. Simvastatin is used as a 
drug to reduce lipid in hypercholesterolaemic patients. 
Moreover, Liao and colleague reported that simvastatin 
exerts beneficial cardiovascular effect independent of 
their lipid lowering property[25], which might be due to its 
antioxidant properties[26]. In the current study, four months 
of simvastatin administration on hypercholesterolaemic 
subjects significantly reduced TC, TG, and LDL. The 
reduction of lipid parameters can be explained on the basis 
of inhibitory effect on hydroxymethylglutaryl coenzyme A 
(HMG-CoA) reductase by simvastatin, the rate limiting step 
in de novo cholesterol synthesis. This pathway decreases 
hepatocytes cholesterol synthesis and subsequently clear 
the LDL from the circulation by LDL receptor of hepatocytes 
cell surface. The effect of simvastatin in lowering TC, TG, 
and LDL levels obtained in our study were similar to those 
described by elsewhere[27,28]. It has been reported that 
simvastatin also has beneficial effect of raising HDL levels 
by unknown mechanism(s)[29,30]. However, the present 
study did not observe any rise in increase of HDL levels 
by simvastatin as previously reported by others[27,28]. These 
discrepancies may be partly explained by variations in the 
participants of the study, such as the severity of dietary 
control, exercise, genetic effect, patient behavior, and 
disease state.
  Simvastatin exerts beneficial cardiovascular effect 
independent of their lipid lowering properties[25] and it 
might be due to its antioxidant effect[26] which is believed 
to come from HDL-associated enzymes, PON1. There are 
considerable numbers of potential pharmacological effect of 
various lipid lowering drugs on PON activity. The increase 
in serum PON1 activity by statin is still unclear due to the 
disagreement of results from earlier studies. In this study, 
simvastatin significantly increased PON1 activity towards 
paraoxon (P<0.05), however, there was a non-significant 
trend for the increase in the PON1 activity towards 
phenyl acetate (P>0.05). Similar results were observed 
in simvastatin treatment that was studied by Tomas and 
colleague[31]. PON1 activity has been shown to be substrate 
dependent and may show varied results for different 
substrates[32]. Paraoxon is the most commonly used substrate 
for the determination of PON1 activity and this level of 
enzyme activity has been shown to reflect the antioxidant 
capacity of the enzyme[33]. At the baseline, PON1 activity 
towards paraxon was unaffected by the differences in sex 
but PON1 activity towards phenyl acetate was significantly 
higher in male than females (P<0.05). After four months of 
simvastatin treatment, PON1 activity towards phenyl acetate 
significantly increased in male subjects (P<0.05), but did 
not changed significantly in female subjects (P>0.05). It 
is rather difficult to explain this finding about mechanism 
underlying the differences, since the number of participants 
was less to make a meaningful comparison, which is a draw 
back of the study. Moreover, most of participants were 
menopause female and more clinical evidence is required 
to support the effect of simvastatin on sex differences. The 
significant increase in PON1 activity in the current study 
may be due to increased PON1 concentration. Recently, 
Deakin and colleague had demonstrated that simvastatin 
increased the nuclear sterol regulating element binding 
protein-2. This protein binds to the paraoxonase promoter 
and cause enhanced promoter activity[34]. After four months 
of simvastatin treatment, the current study observed percent 
change in PON1 activity towards paraoxon was positively 
correlated with percent change of TAS (R2=0.304), which 
indicates PON1 reduced the extent of peroxidation and the 
risk of heart diseases. It is suggested that PON1 inhibits 
lipid peroxidation by hydrolyzing lipid peroxide and 
hydrogen peroxide. On the other hand, it possibly reduces 
oxidative stress and cause a reduction in the inactivation of 
PON1 and thereby leading to the increase of PON1 activity 
as observed after 4 months of treatment.
  In the present study, simvastatin significantly reduced 
CD (4.4%), total peroxide (13.0%) and MDA (15.2%), 
whereas, TAS was significantly increased (27.3%). These 
parameters caused overall significant reduction of OSI 
(24.0%). The effect of simvastatin in lowering CD, total 
peroxide, MDA and increasing TAS levels obtained from our 
study were similar to some previously reported studies [26,30,31]. 
The reductions of lipid peroxide markers imply that PON 
functions by hydrolyzing lipid peroxides since the level of 
lipid peroxidation markers are decreased where as total 
peroxides and MDA, decreased more than CD. However, the 
result did not provide enough clear cut evidence to show the 
precise mechanism since a reduction of lipid peroxidation 
could partly be due to an effect from the decreased in 
lipid levels. In this study, the results demonstrated clearly 
that simvastatin caused a significant reduction of OSI 
in hypercholesterolaemic subjects. It seems therefore 
reasonable to postulate that simvastatin exerts beneficial 
effect on CHD, a mechanism that is beyond its lipid 
modifying properties. This beneficial effect may have an 
impact on the prevention of CHD.
  In conclusion, the present study shows that simvastatin 
increased the TAS and PON1 activities and decreased 
lipid peroxidation and oxidative stress. This might be due 
to antioxidant or pleiotropic properties of simvastatin. A 
clear understanding of the effects of lipid lowering drugs on 
non-lipid risk factors of atherosclerosis will be helpful for 
selection of optimal treatment according to risk profile of 
individual patients. The observations from the current study 
can be applicable to pharmacogenetics and also essential 
for the development of more effective therapy. However, 
strong evidence are needed to substantiate the findings of 
the present study.
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